Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Handelsinvest Investeringsforvaltning

Handelsinvest Investeringsforvaltning reduced its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 34.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,697 shares of the company’s stock after selling 1,400 shares during the period. Handelsinvest Investeringsforvaltning’s holdings in Apellis Pharmaceuticals were worth $159,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Future Financial Wealth Managment LLC purchased a new position in shares of Apellis Pharmaceuticals in the first quarter worth about $29,000. CWA Asset Management Group LLC purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth about $205,000. HC Advisors LLC purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth about $210,000. Woodward Diversified Capital LLC purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth about $210,000. Finally, Whittier Trust Co. purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth about $221,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Trading Up 1.2 %

Shares of APLS stock opened at $35.41 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.02 and a current ratio of 3.77. The stock has a market capitalization of $4.30 billion, a P/E ratio of -10.23 and a beta of 0.88. The company has a 50 day moving average price of $41.80 and a 200 day moving average price of $54.34. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $19.83 and a fifty-two week high of $90.21.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). The firm had revenue of $172.33 million during the quarter, compared to analysts’ expectations of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The business’s quarterly revenue was up 284.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.56) earnings per share. Equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.1 EPS for the current fiscal year.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the transaction, the director now owns 136,998 shares in the company, valued at $5,375,801.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the completion of the transaction, the director now owns 136,998 shares in the company, valued at approximately $5,375,801.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Pascal Deschatelets sold 78,907 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $47,261,880.05. The disclosure for this sale can be found here. Over the last quarter, insiders sold 185,014 shares of company stock worth $8,537,118. Corporate insiders own 6.80% of the company’s stock.

Analyst Ratings Changes

APLS has been the topic of several research reports. Wedbush decreased their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. JPMorgan Chase & Co. lifted their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Wells Fargo & Company reduced their target price on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 23rd. UBS Group reduced their target price on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Finally, Piper Sandler started coverage on shares of Apellis Pharmaceuticals in a research note on Friday, May 31st. They set a “neutral” rating and a $46.00 target price on the stock. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $75.56.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).